NCT05706779 - Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 13, 2023

Primary Completion Date

December 30, 2026

Study Completion Date

May 31, 2029

Conditions

Colorectal CancerBRAF V600E Mutation Positive

Interventions

DRUG

Encorafenib Oral Capsule + Cetuximab

Encorafenib: 4 capsules 75 mg/day (300 mg) , 7 days/7 during 6 weeks Cetuximab: 500mg/m2 intravenous route every 2 weeks (D1, D14, D28), for 3 cycles over 4 weeks.

Trial Locations (1)

Unknown

RECRUITING

Chu - Hôpital Européen Georges Pompidou, Paris